Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Operating expenses:
Research and development expenses	$ 4,527,698	$ 8,004,852	$ 11,231,862	$ 13,848,538
General and administrative expenses	4,156,606	4,691,321	7,550,069	8,270,049
Total operating expenses	8,684,304	12,696,173	18,781,931	22,118,587
Loss from operations	(8,684,304)	(12,696,173)	(18,781,931)	(22,118,587)
Interest income (expenses), net
Interest income	675,209	750,654	1,344,104	1,479,995
Interest expense	(1,187,971)	(995,397)	(2,362,716)	(1,962,242)
Interest income (expenses), net	(512,762)	(244,743)	(1,018,612)	(482,247)
Loss before income taxes	(9,197,066)	(12,940,916)	(19,800,543)	(22,600,834)
Benefit for income taxes	869,169	1,406,021	869,169	1,406,021
Net loss	(8,327,897)	(11,534,895)	(18,931,374)	(21,194,813)
Comprehensive loss	$ (8,327,897)	$ (11,534,895)	$ (18,931,374)	$ (21,194,813)
Per share information:
Net loss per share, basic (in dollars per share)	$ (0.23)	$ (0.37)	$ (0.53)	$ (0.69)
Net loss per share, diluted (in dollars per share)	$ (0.23)	$ (0.37)	$ (0.53)	$ (0.69)
Weighted average common shares outstanding, basic (in shares)	36,693,561	30,802,498	35,754,715	30,616,310
Weighted average common shares outstanding, diluted (in shares)	36,693,561	30,802,498	35,754,715	30,616,310